Use of ezetimibe in the United States and Canada

New England Journal of Medicine

Volumn 358, Issue 17, 2008, Pages 1819-1828

  Jackevicius, Cynthia A ^a,b,e   Tu, Jack V ^b,c,d   Ross, Joseph S ^f   Ko, Dennis T ^c,d   Krumholz, Harlan M ^g,h,i  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h YALE NEW HAVEN HOSPITAL   (United States)

ⁱ YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE PLUS ATORVASTATIN; ANTILIPEMIC AGENT; ASPIRIN PLUS PRAVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOVASTATIN PLUS NICOTINIC ACID; NICOTINIC ACID; PRAVASTATIN; PRAVIGARD; UNCLASSIFIED DRUG;

ARTICLE; CANADA; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG USE; HEALTH CARE COST; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

EID: 42549146702     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa0801461     Document Type: Article

References (35)

1. WebMD, theheart.org. Concerns raised on delay of ezetimibe data. (Accessed March 28, 2008, at http://www.theheart.org/article/829507.do.)
2. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. [Erratum, Lancet 2005;366:1358.]
4. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-97.
5. Drugs@FDA: FDA approved drug products. (Accessed March 28, 2008, at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Search_Drug_Name.)
6. Health Canada. Notice of compliance. (Accessed March 28, 2008, at http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/index_e.html.)
7. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124-8.
8. Product information: Zetia. North Wales, PA: Merck/Schering-Plough Pharmaceuticals, September 2007 (package insert).
9. Product monograph: Ezetrol. Kirkland, QC, Canada: Merck Frosst-Schering Pharma, October 2007 (package insert).
10. Product information: Vytorin. North Wales, PA: Merck/Schering-Plough Pharmaceuticals, September 2007 (package insert).
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. [Erratum, Circulation 2004;110:763.]
12. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27. [Erratum, Can J Cardiol 2006;22:1077.]
13. Pettypiece S. Schering-Plough, Merck probed over ads for Vytorin (Update2). New York: Bloomberg.com, January 16, 2008. (Accessed March 28, 2008, at http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aBVC776LNAoo.)
14. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada 1996 and 2001. Can J Cardiol 2003;19:1359-66.
15. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 2003;168:553-7.
16. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med 2003;115:467-72.
17. Statistics Canada. 2001 Census of Canada. (Accessed March 28, 2008, at http://www12.statcan.ca/english/census01/home/Index.cfm.)
18. Census Bureau home page. (Accessed March 28, 2008, at http://www.census.gov.)
19. Vachris MA, Thomas J. International price comparisons based on purchasing power parity. Month Labor Rev 1999;122(10):3-12.
20. Rouleau JL, Moyé LA, Pfeffer MA, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med 1993;328:779-84.
21. Iglehart JK. Revisiting the Canadian health care system. N Engl J Med 2000;342:2007-12.
22. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-81.
23. The growing burden of heart disease and stroke in Canada 2003. Ottawa: Heart and Stroke Foundation of Canada, May 2003.
24. Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-consumer advertising of prescription drugs. N Engl J Med 2007;357:673-81.
25. Hollon MF. Direct-to-consumer advertising: a haphazard approach to health promotion. JAMA 2005;293:2030-3.
26. Waxman HA. The lessons of Vioxx - drug safety and sales. N Engl J Med 2005;352:2576-8.
27. Mintzes B, Barer ML, Kravitz RL, et al. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ 2002;324:278-9. [Erratum, BMJ 2002;324:1131.]
28. Rawson NSB, Kaitin KI. Canadian and US drug approval times and safety considerations. Ann Pharmacother 2003;37:1403-8.
29. Jackevicius CA, Mamdani MM, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7.
30. Ontario Drug Benefit program formulary. (Accessed March 28, 2008, at http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html.)
31. British Columbia PharmaCare program formulary. (Accessed March 28, 2008, at http://www.health.gov.bc.ca/pharme/formulary/index.html.)
32. Regie de l'assurance maladie Quebec. Registry - list of medications. (Accessed March 28, 2008, at http://www.ramq.gouv.qc.ca/en/regie/lois/ greffe_liste_med.shtml.)
33. Morgan S, Bassett K, Mintzes B. Outcomes-based drug coverage in British Columbia. Health Aff (Millwood) 2004;23(3):269-76.
34. Marra CA, Lynd LD, Anis AH, Esdaile JM. Approval process and access to prescription drugs in Canada. Arthritis Rheum 2006;55:9-11.
35. drugstore.com home page. (Accessed March 28, 2008, at http://www.drugstore.com.)